Literature DB >> 30068642

Contribution of a Multifunctional Polymerase Region of Foot-and-Mouth Disease Virus to Lethal Mutagenesis.

Ignacio de la Higuera1, Cristina Ferrer-Orta2, Elena Moreno1, Ana Isabel de Ávila1, María Eugenia Soria1, Kamalendra Singh3, Flavia Caridi1, Francisco Sobrino1, Stefan G Sarafianos3, Celia Perales1,4,5, Nuria Verdaguer6, Esteban Domingo7,4.   

Abstract

Viral RNA-dependent RNA polymerases (RdRps) are major determinants of high mutation rates and generation of mutant spectra that mediate RNA virus adaptability. The RdRp of the picornavirus foot-and-mouth disease virus (FMDV), termed 3D, is a multifunctional protein that includes a nuclear localization signal (NLS) in its N-terminal region. Previous studies documented that some amino acid substitutions within the NLS altered nucleotide recognition and enhanced the incorporation of the mutagenic purine analogue ribavirin in viral RNA, but the mutants tested were not viable and their response to lethal mutagenesis could not be studied. Here we demonstrate that NLS amino acid substitution M16A of FMDV serotype C does not affect infectious virus production but accelerates ribavirin-mediated virus extinction. The mutant 3D displays polymerase activity, RNA binding, and copying processivity that are similar to those of the wild-type enzyme but shows increased ribavirin-triphosphate incorporation. Crystal structures of the mutant 3D in the apo and RNA-bound forms reveal an expansion of the template entry channel due to the replacement of the bulky Met by Ala. This is a major difference with other 3D mutants with altered nucleotide analogue recognition. Remarkably, two distinct loop β9-α11 conformations distinguish 3Ds that exhibit higher or lower ribavirin incorporation than the wild-type enzyme. This difference identifies a specific molecular determinant of ribavirin sensitivity of FMDV. Comparison of several polymerase mutants indicates that different domains of the molecule can modify nucleotide recognition and response to lethal mutagenesis. The connection of this observation with current views on quasispecies adaptability is discussed.IMPORTANCE The nuclear localization signal (NLS) of the foot-and-mouth disease virus (FMDV) polymerase includes residues that modulate the sensitivity to mutagenic agents. Here we have described a viable NLS mutant with an amino acid replacement that facilitates virus extinction by ribavirin. The corresponding polymerase shows increased incorporation of ribavirin triphosphate and local structural modifications that implicate the template entry channel. Specifically, comparison of the structures of ribavirin-sensitive and ribavirin-resistant FMDV polymerases has identified loop β9-α11 conformation as a determinant of sensitivity to ribavirin mutagenesis.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  antiviral therapy; error threshold; nucleotide recognition; polymerase structure; ribavirin; viral quasispecies

Mesh:

Substances:

Year:  2018        PMID: 30068642      PMCID: PMC6158410          DOI: 10.1128/JVI.01119-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

1.  Error catastrophe and antiviral strategy.

Authors:  Manfred Eigen
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA.

Authors:  Cristina Ferrer-Orta; Armando Arias; Rosa Perez-Luque; Cristina Escarmís; Esteban Domingo; Nuria Verdaguer
Journal:  J Biol Chem       Date:  2004-08-03       Impact factor: 5.157

3.  Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence.

Authors:  Jianxiong Zeng; Haiwei Wang; Xiaochun Xie; Chen Li; Guohui Zhou; Decheng Yang; Li Yu
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

4.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen.

Authors:  S Crotty; D Maag; J J Arnold; W Zhong; J Y Lau; Z Hong; R Andino; C E Cameron
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

5.  Genomic nucleotide sequence of a foot-and-mouth disease virus clone and its persistent derivatives. Implications for the evolution of viral quasispecies during a persistent infection.

Authors:  M Toja; C Escarmís; E Domingo
Journal:  Virus Res       Date:  1999-11       Impact factor: 3.303

6.  Attenuation of Foot-and-Mouth Disease Virus by Engineered Viral Polymerase Fidelity.

Authors:  Devendra K Rai; Fayna Diaz-San Segundo; Grace Campagnola; Anna Keith; Elizabeth A Schafer; Anna Kloc; Teresa de Los Santos; Olve Peersen; Elizabeth Rieder
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

7.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

8.  Foot-and-mouth disease virus type O specific mutations determine RNA-dependent RNA polymerase fidelity and virus attenuation.

Authors:  Chen Li; Haiwei Wang; Tiangang Yuan; Andrew Woodman; Decheng Yang; Guohui Zhou; Craig E Cameron; Li Yu
Journal:  Virology       Date:  2018-02-20       Impact factor: 3.616

9.  Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture.

Authors:  F Sobrino; M Dávila; J Ortín; E Domingo
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

10.  Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.

Authors:  Celia Perales; Rubén Agudo; Hector Tejero; Susanna C Manrubia; Esteban Domingo
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more
  1 in total

1.  Residues within the Foot-and-Mouth Disease Virus 3Dpol Nuclear Localization Signal Affect Polymerase Fidelity.

Authors:  Anna Kloc; Devendra K Rai; Douglas P Gladue; Elizabeth Schafer; Mary Kenney; Elizabeth Rieder
Journal:  J Virol       Date:  2020-08-17       Impact factor: 5.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.